Abstract:Introduction: The lower respiratory tract microbiome is widely studied to pinpoint microbial dysbiosis of diversity or abundance that is linked to a number of chronic respiratory illnesses. However, it is vital to clarify how the microbiome, through the release of microbial metabolites, impacts lung health and oncogenesis. Methods: In order to discover the powerful correlations between microbial metabolites and disease, we collected, under electronic bronchoscopy examinations, samples of paired bronchoalveolar lavage fluids (BALFs) from tumor-burden lung segments and ipsilateral non-tumor sites from 28 lung cancer participants, further performing metagenomic sequencing, short-chain fatty acid (SCFA) metabolomics, and multiomics analysis to uncover the potential correlations of the microbiome and SCFAs in lung cancer. Results: In comparison to BALFs from normal lung segments of the same participant, those from lung cancer burden lung segments had slightly decreased microbial diversity in the lower respiratory tract. With 18 differentially prevalent microbial species, including the well-known carcinogens Campylobacter jejuni and Nesseria polysaccharea , the relative species abundance in the lower respiratory tract microbiome did not significantly differ between the two groups. Additionally, a collection of commonly recognized probiotic metabolites called short-chain fatty acids showed little significance in either group independently but revealed a strong predictive value when using an integrated model by machine learning. Multiomics also discovered particular species related to SCFAs, showing a positive correlation with Brachyspira hydrosenteriae and a negative one with Pseudomonas at the genus level, despite limited detection in lower airways. Of note, these distinct microbiota and metabolites corresponded with clinical traits that still required confirmation. Conclusions: Further analysis of metagenome functional capacity revealed that genes encoding environmental information processing and metabolism pathways were enriched in the lower respiratory tract metagenomes of lung cancer patients, further supporting the oncogenesis function of various microbial species by different metabolites. These findings point to a potent relationship between particular components of the integrated microbiota-metabolites network and lung cancer, with implications for screening and diagnosis in clinical settings.

Integrative metagenomic, transcriptomic, and proteomic analysis reveal the microbiota-host interplay in early-stage lung adenocarcinoma among non-smokers

Characterizing microbiota and metabolomics analysis to identify candidate biomarkers in lung cancer

Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer

Role of Respiratory System Microbiota in Development of Lung Cancer and Clinical Application

Alterations of lower respiratory tract microbiome and short-chain fatty acids in different segments in lung cancer: a multiomics analysis

Dissection of Intratumor Microbiome-Host Interactions at Single-Cell Level in Lung Cancer

Gut mycobiome as a potential non-invasive tool in early detection of lung adenocarcinoma: a cross-sectional study

Smoker and non-smoker lung adenocarcinoma is characterized by distinct tumor immune microenvironments.

Association Studies on Gut and Lung Microbiomes in Patients with Lung Adenocarcinoma

Analyzing lung cancer risks in patients with impaired pulmonary function through characterization of gut microbiome and metabolites

Integrative Proteomic Characterization of Human Lung Adenocarcinoma

The airway microbiota of non‐small cell lung cancer patients and its relationship to tumor stage and EGFR gene mutation

The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment

The characteristics of intratumoral microbial community reflect the development of lung adenocarcinoma

Identification of microbial markers associated with lung cancer based on multi‐cohort 16 s rRNA analyses: A systematic review and meta‐analysis

Pulmonary microbiota signatures adjacent to adenocarcinoma, squamous cell carcinoma and benign lesion

Microbiome and lung cancer: carcinogenic mechanisms, early cancer diagnosis, and promising microbial therapies

In-Depth Metaproteomics Analysis of Oral Microbiome for Lung Cancer

Identifications of the potential in-silico biomarkers in lung cancer tissue microbiomes

Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution

Structure of gut microbiota and characteristics of fecal metabolites in patients with lung cancer